Through an innovative feat of plant biotechnology and vaccine design, researchers in the Biodesign Institute at Arizona State University have successfully turned tobacco plants into vaccine production factories to combat the deadliest form of plague. The vaccine elicits a protective immune response in guinea pigs. The results are considered to be a milestone in the future development of a new vaccine for human use.
Plague, caused by a rod-shaped bacterium called Yersinia pestis, no longer invokes the "black death" feared throughout history, having been widely tamed since the advent of antibiotics. But a new concern has emerged in recent years with respect to bioterrorism.
"There have been discovered some resistant strains to antibiotics and that poses a concern, especially if plague would be used as a bioweapon," said Luca Santi, a research assistant professor at the institute and lead author of the study published in the early online edition of the journal Proceedings of the National Academy of Sciences. "A new vaccine approach would be the best way to prevent infection."
In addition to manmade threats, the Centers for Disease Control estimates 1,000 to 3,000 outbreaks still occur in the world every year as a result of people coming into close contact with rodents infected with fleas that harbor the bacteria.
Particularly worrisome to human health is the pneumonic form of the disease, which can spread by an airborne route after infecting the lungs. It is considered universally fatal if not detected and treated after symptoms arise one to six days after the initial exposure.
Current vaccines against plague are severely limited from widespread adoption by having problems with high adverse reaction rates and side effects.
The research team included Santi, Hugh Mason and Charles Arntzen, all members of the institute's Center for Infectious Disease and Vaccinology. They worked out a new plant-based system to rapidly and stably produce high levels of proteins, called antigens, which conferred immunity against the plague.
"This current work represents a new direction in our research because we've come to the realization that plants also have the potential for the production of antigens that can be purified and delivered by typical intramuscular or subcutaneous injections -- the way most vaccines are normally given," said Mason, an associate professor in the School of Life Sciences. "This new system produces really high levels of antigens in relatively short periods of time."
The researchers modified tobacco plants to make high levels of the plague antigens F1, V and a combination of the two, a so-called F1-V fusion antigen. All are known to be important for the plague bacteria to produce its toxic effects.
The antigens were purified from the plants and injected into guinea pigs. Testing using an aerosolized form of plague was performed by Chad Roy and Robert Webb at the U.S. Army Medical Research Institute of Infectious Disease at Fort Detrick, Maryland. This project was also the first comparison study designed to test more than one kind of antigen during the same challenge.
"The idea with any recombinant subunit vaccine is that you can pick and choose selective antigens that can confer protection and limit the potential for adverse reaction," said Mason.
More than half the vaccinated animals survived the challenge with all forms of the antigen, and guinea pigs vaccinated with V antigen alone had the highest survival rates.
"This study provided validation of our plant expression system, that it can produce the bacterial antigens in a native form that will allow for an appropriate immune response against a bacterial pathogen." Mason.
Critical to the success of the study was a collaboration set up with Anatoli Giritch, Victor Klimyuk and Yuri Gleba, who originally developed the plant expression system at Icon Genetics, located in Halle, Germany.
The group's results are the first to use Icon's viral expression system that adapts the tobacco mosaic virus (TMV) to produce a plant-based vaccine against plague. TMV, a common scourge of the plant world, causes widespread plant disease and can damage and mottle the leaves, flowers and fruits of whole crops. In the system, TMV is simply injected into the leaves of the tobacco plants.
Like most crops, producing vaccines in tobacco plants primarily revolved around issues of speed, low cost and high yield. "The major advantage of the vaccine is the rapidity of the system," said Santi. "In a matter of 10 days, we can go from infecting the plants to harvesting the plants. From there, we purify the antigens in an additional one to two weeks to create the vaccine."
The approach also eliminates the typical year-long lag time necessary to establish and characterize genetically modified, or transgenic plants.
The beauty of system is its potential versatility that can be adapted to fight against other pathogens as well. The research team's next step is to refine their methods to achieve a large-scale commercial production of the vaccine.
The Biodesign Institute at Arizona State University addresses challenges to human health by integrating research in biology, chemistry, physics, medicine, agriculture, environmental science, electronics, engineering and computing. This bold approach ensures discoveries are rapidly converted into applications and adopted by the private sector. For information, visit www.biodesign.org or call (480) 727-8322.
Cite This Page: